Where does obe-cel currently fit in the treatment algorithm for B-cell ALL, and how might this evolve?
カートのアイテムが多すぎます
カートに追加できませんでした。
ウィッシュリストに追加できませんでした。
ほしい物リストの削除に失敗しました。
ポッドキャストのフォローに失敗しました
ポッドキャストのフォロー解除に失敗しました
Where does obe-cel currently fit in the treatment algorithm for B-cell ALL, and how might this evolve?
-
ナレーター：
-
著者：
The ALL Hub was pleased to speak with Claire Roddie, University College London Cancer Institute, London, UK. We asked, where does obecabtagene autoleucel (obe-cel) currently fit in the treatment algorithm for B-cell acute lymphoblastic leukemia (B-cell ALL), and how might this evolve?
In this interview, Roddie discusses the current regulatory approvals for obe-cel for the treatment of B-cell ALL and the key findings from the phase Ib/II FELIX trial. Roddie also outlines the evolving role of obe-cel in the treatment of ALL, including ongoing studies investigating its use earlier in the treatment paradigm, and concludes by highlighting the importance of developing biomarker assays to monitor patients following CAR T-cell infusion.
This educational resource is independently supported by Autolus. All content was developed by SES in collaboration with an expert steering committee. Funders were allowed no influence on the content of this resource.
Hosted on Acast. See acast.com/privacy for more information.